The country of origin of Cyclophosphamide for Injection USP in dosage form
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Key passages, quoted from the ruling
- In this case, we find the processing of the active ingredient Cyclophosphamide (made in India) into the final Cyclophosphamide for Injection in dosage form in China does not result in a substantial transformation and the country of origin will be India.
Ruling text
In your letter dated June 2, 2025, you requested a country of origin ruling on Cyclophosphamide for Injection in dosage form. Cyclophosphamide for Injection, imported in 500 mg/vial, 1 gm/vial, and 2 gm/vial, is an alkylating drug which is a type of chemotherapy drug used primarily in the treatment of various cancers. It is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of the ovary, retinoblastoma, and breast carcinoma.
Cyclophosphamide for Injection is also indicated for the treatment of minimal change nephrotic syndrome in pediatric patients. You state the active pharmaceutical ingredient (API), Cyclophosphamide, is manufactured in India, and the finished Cyclophosphamide Injection in dosage form is made in China. In China, the API (Cyclophosphamide) will be processed into the final Cyclophosphamide for Injection in dosage form. When determining the country of origin, the substantial transformation analysis is applicable.
See, e.g., Headquarters Ruling Letter (“HQ”) H301619, dated November 6, 2018. The test for determining whether a substantial transformation will occur is whether an article emerges from a process with a new name, character, or use different from that possessed by the article prior to processing. See Texas Instruments Inc. v. United States, 681 F.2d 778 (C.C.P.A. 1982). This determination is based on the totality of the evidence.
See National Hand Tool Corp. v. United States, 16 C.I.T. 308 (1992), aff’d, 989 F.2d 1201 (Fed. Cir. 1993). In this case, we find the processing of the active ingredient Cyclophosphamide (made in India) into the final Cyclophosphamide for Injection in dosage form in China does not result in a substantial transformation and the country of origin will be India.
This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov.
The holding set forth above applies only to the specific factual situation and merchandise description as identified in the ruling request. This position is clearly set forth in Title 19, Code of Federal Regulations (CFR), Section 177.9(b)(1). This section states that a ruling letter is issued on the assumption that all of the information furnished in the ruling letter, whether directly, by reference, or by implication, is accurate and complete in every material respect.
In the event that the facts are modified in any way, or if the goods do not conform to these facts at time of importation, you should bring this to the attention of U.S. Customs and Border Protection (CBP) and submit a request for a new ruling in accordance with 19 CFR 177.2. Additionally, we note that the material facts described in the foregoing ruling may be subject to periodic verification by CBP.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N349744).